Truist Sees Upside in Lantheus Holdings, Inc. (LNTH) Despite PYLARIFY Pressure

We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. LNTH is one of them.

On December 11, TheFly reported that Truist Securities upgraded LNTH from Hold to Buy and raised its price target to $80, reflecting a more optimistic view of the company’s growth prospects and belief that the current valuation underrates future revenue and earnings potential.

The upgrade reflected expected profit re-acceleration into late 2025 and beyond and was supported by LNTH’s strong financial performance and strategic positioning relative to industry peers.

This positive view is connected to Lantheus Holdings, Inc. (NASDAQ:LNTH)’s third-quarter 2025 results released on November 6th, in which the company reported $384 million in revenue, adjusted EPS of $1.27, and $94.7 million in free cash flow, despite some pressure on its core PYLARIFY franchise.

Lantheus Holdings, Inc. (NASDAQ:LNTH) is a leading radiopharmaceutical-focused company dedicated to providing innovative diagnostic and therapeutic products to improve patient outcomes.

While we acknowledge the risk and potential of LNTH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LNTH and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Blue Chip Stocks to Buy Under $50 and11 Best Low Priced Dividend Stocks to Buy According to Analysts.

Disclosure: None.